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Introduction 
Although relatively rare, meningococcal disease rep-
resents a global health problem being still the leading 
infectious cause of death in childhood with an over-
all mortality around 8% [1]. Neisseria meningitidis 
is pathogenic only in humans and it colonizes the na-
sopharynx asymptomatically in up to 5-10% of the adult 
population, although occasionally can cause invasive 
disease [2]. Meningococcal infection occurs in small 
clusters throughout the world with seasonal variation 
and accounts for a variable proportion of epidemic bac-
terial meningitis. The meningococcal invasive disease 
is associated only with six serogroups classified on the 
basis of polysaccharide capsule surrounding the bacte-
rium (A, B, C, W-135, X, and Y) [3]. Serogroups A, B, 
and C account for most cases of meningococcal disease 
throughout the world. In particular, serogroups A and C 
are responsible for large epidemics in Africa and Asia, 
whereas serogroups B and C cause disease predominant-
ly in industrialized and newly industrialized countries in-
cluding Europe and the Americas [3]. Recently, groups 
W-135 and X (predominantly in Africa) and group Y (in 
the United States and European countries) have emerged 
as important disease-causing isolates [3, 4].
Meningococcal disease occurs sporadically in industrial-
ized countries with an incidence of 0.35 cases per 100,000 
population in the United States and 1.01 per 100,000 in 
Europe [1, 3].The major disease burden is in developing 
countries in which the incidence can be higher than 500 
per 100,000, especially in the area of sub-Saharan Africa 
known as the meningitis belt (it stretches from Senegal in 
the west to Ethiopia in the east) [1, 3]. During the dry sea-
son between December to June, dust winds, cold nights 
and upper respiratory tract infections combine to damage 
the nasopharyngeal mucosa, increasing the risk of menin-
gococcal disease. At the same time, transmission of N. 
meningitidis may be facilitated by overcrowded housing 
and by large population displacements at the regional lev-
el due to traditional markets. This combination of factors 
explains the large epidemics which occur during the dry 
season in the meningitis belt [4, 5]. 
Since the majority of deaths occur in the first 24 hours, 
the challenge for the pediatricians is to identify those 
patients who will progress from nonspecific early pres-
entation to fulminant disease. 
Clinical presentations of meningococcal 
disease
Meningococcal disease usually develops within 1 to 14 
days following acquisition of N. meningitidis in the na-
sopharynx [6, 7]. The features that appear earliest (i.e. 
within the first 4-6 h of the onset of meningococcal dis-
ease) are common to many self-limiting viral illnesses 
seen in primary care [1, 2, 6]. Meningococcal meningi-
tis is the most commonly recognized presentation glo-
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Summary
Although relatively rare, meningococcal disease represents a 
global health problem being still the leading infectious cause of 
death in childhood with an overall mortality around 8%. Menin-
gococcal meningitis is the most commonly recognized presenta-
tion, accounting for 80% to 85% of all reported cases of menin-
gococcal disease (in half of these cases sepsis is also present con-
comitantly). The remaining 15-20% of cases are most commonly 
bloodstream infections only. Meningococcal serogroups A, B, and 
C account for most cases of meningococcal disease throughout 
the world. Recently, serogroups W-135 and X (predominantly in 
Africa) and group Y (in the United States and European countries) 
have emerged as important disease-causing isolates. Despite 
recent advances in medical management, the mortality rate of 
fulminant meningococcemia ranges from 15% to 30%. However, 
among survivors, 10-30% could have long term sequelae (i.e. 
sensoneural hearing loss, seizure, motor problems, hydrocepha-
lus, mental retardation, and cognitive and behavioral problems). 
Considering the clinical severity of meningococcal disease, pre-
vention represents the first approach for avoiding serious com-
plications and possible deaths. The availability of new vaccines 
able to cover the emerging serotypes including A and Y as well as 
the availability on the market of new products that could prevent 
meningococcal B infection represent a great opportunity for the 
decrease of the burden of this complicated disease. 
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bally, accounting for 80% to 85% of all reported cases 
of meningococcal disease (in half of these cases sepsis is 
also present concomitantly), although bloodstream infec-
tion may be under-recognized. The remaining 15-20% of 
cases are most commonly bloodstream infections [1, 2].
Initial unspecific symptoms and clinical presentation 
may differ according to the age of patients. Fever can be 
the first symptom to be noticed in children younger than 
5 years, whereas headache is often the first to be seen in 
those older than 5 years [1, 2]. The majority of children 
developed fever at some point and most young children 
appear irritable. Loss of appetite, nausea, and vomiting 
are early features for all age groups, with many children 
also having upper respiratory symptoms (otalgia, sore 
throat and coryza) [1, 2]. Sore throat can be a frequent 
complaint in teenagers aged 15 to 19-years [1, 2]. These 
features, which are not specific to meningococcal dis-
ease, lasted for about 4 h in younger children but as long 
as 8 h in adolescents. Symptoms progress rapidly over a 
period of a few hours [1, 2].
Acute meningococcaemia presents in a nonspecific 
manner with fever, lethargy, reduced feeding, headache, 
nausea and vomiting, cold or discoloured extremities, 
arthralgia and myalgia [2]. Neck stiffness is typicall ab-
sent. The clinical signs of sepsis are fever, tachycardia, 
and tachypnea. A specific characteristic of a meningo-
coccal sepsis is its rapid progression. The cardinal fea-
ture of a meningococcal sepsis is the purpuric rash (Fig. 
1), which is a late sign of the disease and consists in the 
beginning of erythema but later in petechiae and purpura 
characterized by dermal microvascular thrombosis and 
perivascular hemorrhage [8].
Thompson et al. have identified three important clinical 
features that are signs of early acute meningococcaemia 
in children and adolescents [1]. These features are rep-
resented by leg pain, cold hands and feet, and abnormal 
skin colour and generally occur within the first 12 h of 
the onset of illness. Cold hands and feet, and abnormal 
skin colour are features of early sepsis that represent 
changes in the peripheral circulation. Leg pain is less 
well recognised, although pain in the limbs, with or 
without refusal to walk, could be a response to a range 
of inflammatory mediators released during the early sep-
tic process (tumour necrosis factor or other cytokines, 
or other pro-inflammatory mediators). The presence of 
these three features also suggests that vital signs (i.e. 
pulse, respiratory rate, and capillary return) might also 
be abnormal.
In the rash phase, there is a possible differential diag-
nosis with other diseases leading to a petechial rash [8]. 
It is important to observe that approximately 95-99% 
of children with fever and petechiae will have a cause 
other than meningococcal infection (i.e. enterovirus or 
adenovirus infection), and the incidence of meningo-
coccemia in these patients accounts for 2 to 20% of the 
cases. However, it may not be easy to distinguish be-
tween the two without investigations and/or a period of 
observation [2, 8]. Wells et al. analyzed the likelihood 
of a meningococcal infection in children with an acute 
nonblanching rash [9]. From the 233 children studied, 
11% had a meningococcal infection: they were ill, had 
fever of ≥ 38.5°C, and had a delayed capillary refill time. 
Laboratory investigations were not helpful in distin-
guishing meningococcal cases. A comparable study was 
carried out by Nielsen et al. [10]: from 264 infants and 
children hospitalized with fever and skin hemorrhages, 
15% had meningococcal disease. The patients with skin 
hemorrhages of characteristic appearance universally 
distributed and a minimum diameter of 2 mm as well as 
with poor general condition had a likelihood of 97% of 
having a meningococcal infection [10].
The purpuric rash may progress to purpura fulminans, 
which is a cutaneous manifestation of disseminated in-
travascular coagulation. It presents as a purpuric rash 
and symmetric gangrene that often necessitates amputa-
tion and is often associated with a shock state charac-
terized by the rapid onset of hypotension, acute adrenal 
hemorrhage (the Waterhouse-Friderichsen syndrome), 
and multiorgan failure (Fig. 2) [4, 8] In these cases death 
can occur within 24 hours [4, 8].
Fig. 1. purpuric rash in meningococcal sepsis. Fig. 2. gangrene caused by Neisseria meningitidis.
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Meningeal infection resulting from hematogenous spread 
and is similar to other forms of acute purulent meningitis, 
with a sudden onset of headache, fever, and stiffness of the 
neck (i.e. classical triads observed more often in teenag-
ers), sometimes accompanied by nausea, vomiting, pho-
tophobia, an altered mental status and seizures [1, 2, 8]. 
In infants, meningeal infection may have a slower onset, 
with nonspecific signs and without stiffness of the neck; a 
bulging fontanelle is occasionally noted [1, 2, 6]. 
Pneumonia occurs in 5-15% of patients with invasive 
meningococcal disease [4]. Meningococcal pneumonia 
may not always be diagnosed because isolation of the or-
ganism from sputum does not distinguish persons who are 
carriers of the bacteria from those with pneumonia caused 
by N. meningitidis and because physicians may not con-
sider the organism as a possible cause of pneumonia [4].
Much less frequently other syndromes are associated 
with meningococcal disease, including conjunctivitis, 
otitis media, epiglottitis, arthritis, rabdomyolisis, ure-
thritis, and pericarditis [4]. Acute peritonitis as initial 
manifestation of meningococcemia is also described in 
worldwide literature [11]. In rare cases, patients may 
present with chronic meningococcemia, a syndrome 
characterized by prolonged, intermittent fevers, rash, ar-
thralgias, and headaches [4].
Serious outcomes of meningococcal 
disease 
Meningococcal disease is a life-threatening disease, re-
lated with serious complication and sequelae. Despite 
recent advances in medical management, the mortality 
rate of fulminant meningococcemia ranges from 15% 
to 30% [1, 2, 4]. However, many children who survive 
the initial phase of shock develop vascular insufficiency, 
compartment syndrome, or peripheral gangrene. Among 
initial survivors, 10-30% present with skin necrosis and 
limb ischemia needing orthopedic surgical management 
such as debridement, skin grafting, muscular flap cover-
age for limb salvage and, sometimes, even limb ampu-
tation [4]. Children requiring surgery for purpura ful-
minans are often limited by physical disability due to 
amputation, scarring, and abnormal bone growth. 
The incidence rate of residual abnormalities in post men-
ingitic children is approximately 15% (with a range of 
10% to 30%) [12]. The most common sequelae in post-
meningitis children are sensoneural hearing loss, seizure, 
motor problems, hydrocephalus, mental retardation, and 
cognitive and behavioral problems [12]. Among risk 
factors associated with sequele due to meningitis, there 
are duration of illness before admission, presence of 
convulsion, focal neurologic deficits, depressed level of 
consciousness, absence of petechiae on admission and 
low cerebrospinal fluid glucose. 
Antibiotic therapy and prophylaxis  
in meningococcal disease
Early recognition of children with meningococcal in-
fection is mandatory in order to avoid the develop-
ment of sequelae. Identification of N. meningitidis in 
blood as well as in cerebrospinal fluid (CSF) by cul-
ture and/or polymerase chain reaction is mandatory for 
etiologic diagnosis [1, 2, 4]. In some cases, blood and 
CSF may result negative because of previous oral an-
tibiotic therapy. However, in meningococcal disease 
intravenous administration of antibiotics for 7-10 days 
is recommended [13, 14]. Usually, 3rd generation ce-
phalosporins (e.g. ceftriaxone 100 mg/kg/day i.v. in one 
daily dose or cefotaxime 100 mg/kg/day i.v. divided in 
three times per day) represent the recommended treat-
ment of bacterial meningitis and are effective also in 
meningococcal cases [13, 14]. For this reason, 3rd gen-
eration cephalosporins are usually maintained until the 
end of treatment, although penicillin G represents a nar-
row spectrum drug that could be used for the treatment 
of meningococcal cases [13, 14].
In order to avoid outbreaks, taking in account that the 
status of carrier of N. meningitis in the nasopharynx is 
rarely reported, prophylaxis of close contacts of the in-
dex case (i.e. family and school contacts) is recommend-
ed [14]. Close contacts have to be considered persons 
who remain with the index case for more than 4 hours in 
the 7 days before. In these cases, rifampicin 10 mg/kg/
day in two daily doses orally for two days in those aged 
< 1 months, rifampicin 20 mg/kg/day in two daily doses 
orally for two days in those aged 1 months - 18 years 
(with a maximum dosage of 600 mg twice per day for 
two days) and ciprofloxacin 500 mg once orally in those 
aged > 18 years are the recommended approach [14]. 
Conclusions
Considering the clinical severity of meningococcal dis-
ease, prevention represents the first approach for avoiding 
serious complications and possible deaths. The availabil-
ity of new vaccines able to cover the emerging serotypes 
including A and Y [15] as well as the availability on the 
market of new products that could prevent meningococ-
cal B infection [16] represent a great opportunity for the 
decrease of the burden of this complicated disease. 
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